Translating a gene expression signature for multiple myeloma prognosis into a robust high-throughput assay for clinical use

Background Widespread adoption of genomic technologies in the management of heterogeneous indications, including Multiple Myeloma, has been hindered by concern over variation between published gene expression signatures, difficulty in physician interpretation and the challenge of obtaining sufficient genetic material from limited patient specimens.